Disclosures for "Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System Atrophy "
-
Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics. Dr. Stamler has stock in Alterity Therapeutics.
-
Cynthia Wong has received personal compensation for serving as an employee of Alterity Therapeutics. An immediate family member of Cynthia Wong has received personal compensation for serving as an employee of RefleXion Medical. Cynthia Wong has stock in Teva. An immediate family member of Cynthia Wong has stock in 10x Genomics.
-
Paula Trujillo Diaz has nothing to disclose.
-
Margaret Bradbury has received personal compensation for serving as an employee of Alterity Therapeutics. The institution of Margaret Bradbury has received research support from Alterity Therapeutics.
-
Christine Lucas has received personal compensation for serving as an employee of Alterity Therapeutics, Inc.
-
Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark . The institution of Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for HD Insights. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from Genentech/ Roche.